What Do Analysts Suggest For Actinium Pharmaceuticals, Inc. (ATNM)

0
13

Actinium Pharmaceuticals, Inc. (ATNM) will report its next earnings on Sep 07 AMC. The company reported the earnings of $-0.04/Share in the last quarter where the estimated EPS by analysts was $-0.07/share. The difference between the expected and actual EPS was $0.03/share, which represents an Earnings surprise of 42.9%.

Many analysts are providing their Estimated Earnings analysis for Actinium Pharmaceuticals, Inc. and for the current quarter 3 analysts have projected that the stock could give an Average Earnings estimate of $-0.05/share. These analysts have also projected a Low Estimate of $-0.05/share and a High Estimate of $-0.04/share.

Some buy side analysts are also providing their Analysis on Actinium Pharmaceuticals, Inc., where 5 analysts have rated the stock as Strong buy, 0 analysts have given a Buy signal, 0 said it’s a HOLD, and 0 analysts rated the stock as Sell. (These Recommendations are for the Current Month Only reported by Yahoo Finance.)

When it comes to the Analysis of a Stock, Price Target plays a vital role. Analysts reported that the Price Target for Actinium Pharmaceuticals, Inc. might touch $6 high while the Average Price Target and Low price Target is $4.29 and $3 respectively.

The Relative Volume of the company is 0.95 and Average Volume (3 months) is 1.59 million. The company’s P/E (price to earnings) ratio is 0 and Forward P/E ratio of 0.

The company shows its Return on Assets (ROA) value of -99.9%. The Return on Equity (ROE) value stands at -127.9%. While it’s Return on Investment (ROI) value is 0%.

While looking at the Stock’s Performance, Actinium Pharmaceuticals, Inc. currently shows a Weekly Performance of 5.61%, where Monthly Performance is 10.79%, Quarterly performance is 43.13%, 6 Months performance is 65.52% and yearly performance percentage is 8.69%. Year to Date performance value (YTD perf) value is 3.51%. The Stock currently has a Weekly Volatility of 6.84% and Monthly Volatility of 5.91%.

SHARE